Now I have everything I need. Let me compile the final review.

---

## Summary

HYPOGENEAGENT proposes an LLM-driven framework that transforms cluster annotation and resolution selection in single-cell/Perturb-seq analysis into a quantifiable optimization problem. An LLM agent generates ranked GO hypotheses for each cluster's gene signature; the paper then derives a Resolution Score from intra-cluster agreement (ICS) and inter-cluster distinctiveness (ICD) of these hypotheses, selecting the Leiden resolution that maximizes the score. Stage 1 systematically benchmarks LLM backbones, prompt designs, and embedding methods on curated GOBP gene sets. Stage 2 applies the fixed configuration to K562 Perturb-seq data and compares the selected resolution against silhouette, modularity, and functional enrichment baselines.

## Strengths

1. **Novel formalization of a biology-aware Resolution Score.** The paper introduces RSₖ = w·ICSₖ + (1−w)(1−ICDₖ), which operationalizes the traditionally heuristic resolution-selection problem as a concrete, optimizable objective grounded in LLM-generated functional annotations. This is a clean conceptual advance over existing biology-agnostic metrics.

2. **Well-executed Stage 1 benchmark for LLM/prompt/embedding configuration.** The paper evaluates multiple LLMs (GPT-4o, GPT-o3, GPT-5, Gemini-2.0-flash, Gemini-2.5-pro), prompt designs, embedding methods, and temperature settings on 100 curated GOBP gene sets. The systematic ablation—showing that thinking LLMs (GPT-o3) outperform non-thinking ones and that the hypothesis prompt yields ranked, confidence-calibrated predictions whose top-1 aligns best with ground truth (Figures S1d, S2)—provides solid empirical justification for the fixed configuration used downstream.

3. **Explicit comparison with traditional metrics and their limitations.** Section 4.4 methodically examines silhouette score, modularity, and functional enrichment, explaining why each fails to capture biological interpretability (e.g., silhouette assumes convex geometry; modularity is insensitive to small clusters). The paper then shows that HypoGeneAgent's selected resolution is consistent with enrichment-based selection, positioning the method relative to established baselines.

4. **Sensitivity analysis of the weight parameter w.** Figure S5 tests w ∈ [0,1] and reveals that while the overall optimal resolution is stable, outlier clusters respond differently to w—a finding that the paper correctly interprets as a signal for further biological investigation rather than a weakness.

## Weaknesses

### Major

1. **No validation against the available ground-truth perturbation labels.** The K562 Perturb-seq dataset (Replogle et al. 2022) contains known guide-RNA→gene assignments. This provides a natural external gold standard: one could measure how well each resolution's clusters separate different perturbation targets (e.g., via ARI, NMI, or homogeneity). The paper does not perform this analysis. Instead, validation relies entirely on internal consistency (clean UMAPs, the Resolution Score itself) and on GO enrichment analysis, which shares the same GO vocabulary as the agent's hypotheses. The paper claims to "recover known perturbation effects" and "exhibit alignment with known pathway," but these claims are unsubstantiated without a quantitative comparison against the available perturbation identities. This is the single most important gap: the evaluation does not measure the quantity the paper centrally cares about.

2. **The comparison with traditional methods is shallow and does not establish superiority.** The paper shows that silhouette, modularity, and the Resolution Score all peak at different resolutions (respectively ~0.5–0.6, ~0.7, and 0.4–0.5), and discusses why the classical metrics have limitations. But it never provides a quantitative basis for claiming that the HypoGeneAgent-chosen resolution is *biologically better*. The enrichment analysis (Section 4.4.3) is cited as convergent evidence, but since it also operates in GO-term space, it is not an independent adjudicator. Without statistical tests or external validation, "superior biological interpretability" (stated in the abstract and conclusion) is not supported.

3. **The Resolution Score measures LLM self-consistency, not directly biological validity.** High ICS means the LLM produces similar descriptions for the same cluster; low ICD means descriptions differ across clusters. These quantities capture *consistency of the LLM's reasoning* but are not validated proxies for functional coherence. The paper provides no evidence that ICS/ICD scores correlate with actual biological separation (e.g., whether clusters with low ICD contain genes from truly distinct pathways). The Stage 1 benchmark validates the LLM's annotation accuracy on curated gene sets, but that does not guarantee that ICS/ICD on real (noisier) cluster signatures correspond to meaningful biology. This inherent limitation of the approach should be more openly acknowledged and, if possible, bounded by external validation.

### Minor

4. **Justification of the weight w=1/3 is thin.** The paper states this was chosen by "a small grid search" that "gave a stable ordering of resolutions across data sets" without reporting the grid range, the scoring criterion for stability, or whether the optimal resolution is invariant across reasonable w values. Figure S5 partially addresses this by showing w-sweep behavior, but the lack of documentation for the initial search weakens the claim of objectivity.

5. **Evidence retrieval (GO/KEGG/PubMed) is not ablated.** Section 3.3 mentions that the agent retrieves functional summaries from domain databases, but no experiment evaluates whether this retrieval step improves annotation quality over a plain LLM call. Given that the paper positions the method as an "agent" (not just an LLM), the added value of the retrieval component should be isolated.

6. **No runtime or cost analysis.** The conclusion states the pipeline is "orders of magnitude faster than manual curation" and "computationally efficient," but no timing, token costs, or API call counts are reported. For practical adoption, this information is essential.

### Trivial

- Figure axes in the parsed version are sometimes hard to read (small fonts, overlapping labels in box plots).
- The phrase "comparation" (Section 4.4 heading) is a typo for "comparison."

## Nice-to-Haves

- Compute ARI/NMI against known perturbation groups in the K562 dataset to provide the missing ground-truth anchor.
- Add a direct comparison between GPT-o3 + retrieval vs. GPT-o3 without retrieval on the GOBP sets to quantify the value of the retrieval step.
- Report per-cluster GO term enrichment at the selected vs. alternative resolutions to show concrete biological differences between resolution choices.
- Include a statistical test (e.g., Mann-Whitney U) comparing Resolution Score distributions between adjacent resolutions to establish that the optimum is not just noise.
- Provide a table of approximate API costs and wall-clock times for the full resolution sweep.

## Removed Points

*These points are flagged to be removed — treat them with caution.*

- Harsh critic's claim about reproducibility ("prompt templates are only in the appendix") — REMOVED per rules: the parser strips appendix content; prompts exist in the original submission.
- Harsh critic's claim that "the choice of w is arbitrary" without acknowledging Figure S5 — REMOVED as factually incomplete (the paper does provide sensitivity analysis in Figure S5).
- Harsh critic's claim that silhouette and modularity optima (0.5–0.7) and HypoGeneAgent optima (0.4–0.5) "fall within the same range" — PARTIALLY REMOVED because 0.4 is below 0.5, though the broader point about lack of superiority evidence is retained in Weakness #2.
- Strength Finder's claim that the Resolution Score "recovers known perturbation biology better than classical metrics" — MOVED to Removed Points because it conflicts with verified Weakness #1 (no ground-truth validation); the underlying evidence (UMAP, enrichment) is still acknowledged in Strengths #3 but the superiority claim is dropped.
- Strength Finder's claim that Stage 2 demonstrates the score "selects a biologically meaningful granularity" — toned down; the evidence is present but incomplete, so this is captured in Strength #3 with appropriate caveats.

## Novel Insights

None beyond the paper's own contributions. The core insight—that the consistency of LLM-generated functional hypotheses can be used as a quantitative criterion for resolution selection—is the paper's novel contribution. The reviews do not surface an orthogonal novel observation about the method or data.

## Suggestions

1. **Ground-truth validation is essential.** Add an experiment computing ARI/NMI between clusters at each resolution and the known perturbation group labels (guide-targeted genes or known functional categories) from the Replogle et al. K562 dataset. Show that the resolution selected by HypoGeneAgent achieves higher scores on these external metrics than resolutions selected by silhouette, modularity, or enrichment. This single addition would most directly address the paper's central weakness.

2. **Clearly separate internal from external validity claims.** The abstract and conclusion should distinguish what the paper demonstrates (internal consistency of LLM annotations as a selection criterion) from what it does not yet demonstrate (that this criterion yields biologically superior clusterings compared to alternatives). Currently the two are conflated.

3. **Ablate the evidence retrieval module** on the GOBP benchmark to show whether the "agent" component (retrieval + self-verification) improves annotation accuracy over a plain GPT-o3 call with the same hypothesis prompt.

4. **Report runtime and cost** for the full resolution sweep (10 resolutions, ~20 clusters each) in terms of API calls, tokens, approximate cost, and wall-clock time.

## Score and Decision

**Round 1 bracketing.** The paper sits between the low-band anchors (DrugAgent at 2.50, scMPT at 3.40 — clearly weaker, with more fundamental issues) and the high-band anchors (CellPLM at 6.50, GeSubNet at 8.00 — stronger, with more thorough evaluation). The plausible range is 4.0–6.0.

**Round 2 narrowing.** Compared to ZerOmics (4.67, Reject), which had a promising idea undermined by evaluation flaws and overclaimed "zero-shot" framing, HYPOGENEAGENT has stronger novelty (explicitly defined biology-aware resolution criterion) but a similar degree of evaluative incompleteness. Compared to IFPCA+ (5.00, Reject), which offered incremental improvement with weak theory, HYPOGENEAGENT has a more original contribution but comparably thin central validation. Compared to Evaluating SC Foundation Models (5.00, Reject), which was comprehensive but shallow, HYPOGENEAGENT proposes a new method rather than just benchmarking. The paper's Stage 1 execution is solid, and the core idea is genuinely novel, but the central claim (biologically superior resolution selection) is not adequately supported due to the missing ground-truth validation.

**Final score: 5.0.** This is a borderline reject. The contribution is real and the methodology is sensible, but the paper's most important claim is under-evidenced. Acceptance would require resolving the major evaluation gaps, particularly the missing external validation against known perturbation labels.

**Anchors consulted (all rounds):**
- DrugAgent (2.50, R1) — clearly weaker method with less coherent contribution.
- scMPT (3.40, R1) — weaker, less novel contribution.
- ZerOmics (4.67, R1/R2) — similar level: novel idea but evaluation doesn't fully support claims.
- LLM4GRN (4.33, R2) — interesting idea but weak evaluation; comparable issue.
- sCellTransformer (4.50, R2) — similar rejection-tier work with evaluation gaps.
- IFPCA+ (5.00, R1/R2) — comparable: incremental improvement, limited insight.
- Evaluating SC Foundation Models (5.00, R1/R2) — comparable: solid but limited in novelty.
- CellPLM (6.50, R1) — stronger: more thorough evaluation, accepted.
- GeSubNet (8.00, R1) — clearly stronger: rigorous multi-step validation.
- MMQA (8.00, R1) — clearly stronger on a different problem domain.

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>